Lonza Group - Analyst consensus and technical picture on Thursday
18.06.2026 - 13:04:00 | ad-hoc-news.de
Edited by ad hoc news Chart & Technicals Desk. Verified prior to publication on 06/18/2026, 11:45 CET. Details in the imprint.
Lonza Group (CH0013841017) remains a liquid Swiss large cap in the contract development and manufacturing space. With no new ad-hoc releases or major broker actions on Thursday, investors are focusing on the current analyst consensus and the stock’s technical picture.
All news and background on Lonza Group stock
Key figures, past disclosures and further context on Lonza Group can be found in the dedicated topic section and on the company’s investor relations site.
What current data providers show
Lonza Group stock is listed on the SIX Swiss Exchange under the ticker LONN and closed the last session around the mid-CHF 550 range, according to recent quote data from Morningstar. This keeps the company clearly in Swiss large-cap territory, with a multi-billion Swiss franc valuation.
MarketScreener describes Lonza Group as a leading global contract development and manufacturing organization for pharmaceutical and biotechnology products, reflecting the company’s strong position in the CDMO market. The profile highlights activities across biologics, small molecules and cell and gene technologies.
Thursday focus on chart and consensus
With no fresh regulatory filings, M&A announcements or earnings updates on Thursday, the market lens shifts to how Lonza shares trade versus recent ranges and what analysts expect from the CDMO specialist. The stock remains within its 52-week range, leaving room for interpretation of the medium-term trend.
According to Morningstar’s latest snapshot, Lonza Group shows a 52-week trading corridor roughly between the high-CHF 460s and the low-CHF 610s, underlining a notable volatility band for a blue-chip name. That range frames current levels within the broader move of the past year.
The chart picture on the SIX
Recent quote data suggest that Lonza Group shares are trading closer to the middle of their 52-week bandwidth than to the extremes, pointing to a consolidating rather than a stretched chart setup for now. This is relevant for technically oriented investors monitoring potential support and resistance zones.
On a multi-month view, the stock has previously tested both the lower and upper bounds of this range, which can serve as technical reference points for market participants who track prior lows and highs for timing decisions. Overall, Thursday’s context is more about levels than new headlines.
How analysts view Lonza today
Analyst platforms such as MarketScreener continue to show a broad coverage universe for Lonza Group, reflecting its role as a core holding in the European life-sciences sector. The mix includes global investment banks and regional brokers, which feed into the published consensus numbers.
These consensus snapshots typically aggregate target prices, rating distributions and earnings expectations, giving investors a structured view of how the sell-side currently benchmarks Lonza Group against peers in the outsourced pharma services space. Net-net, the stock remains under close professional scrutiny.
The business behind the stock
Lonza Group generates most of its revenue as a contract development and manufacturing organization for pharmaceutical and biotech customers, including biologics, small molecules and advanced therapies. The company provides services from early development through large-scale commercial production for global clients.
Where the stock trades today
The shares of Lonza Group (CH0013841017) trade on the SIX Swiss Exchange at CHF 555.40 as of 06/18/2026, 11:30 CET, based on the latest available delayed data from Morningstar.
Key facts on Lonza Group stock
- Company: Lonza Group AG
- ISIN: CH0013841017
- WKN: 618132
- Ticker: LONN
- Venue: SIX Swiss Exchange
- Price (as of 06/18/2026, 11:30 CET): 555.40 CHF
- Market cap: 41,000,000,000 CHF (as of 06/18/2026, based on recent quote and free data provider estimates)
- Sector / Industry: Health Care - Life Sciences Tools & Services / CDMO
- Index membership: SMI
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
